Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
US11299543B2 · kind B2 · utility
0Cited by
38References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 1, 2017 |
| Grant date | Apr 12, 2022 |
| Priority date | — |
| Expiry date | May 13, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.